Qualifying Therapeutic Discovery Project Grants for the State of Virginia
The listings below represent the applicants that have been awarded a Qualifying Therapeutic Discovery Program Grant.
The project descriptions below were extracted from the applicant certification forms as submitted.
| Applicant Name | Project Name | Grants Awarded for 2009 | Grants Awarded for 2010 |
|---|---|---|---|
| Adaptive Methods, Inc | Rapid Portable Biosensor | $ 75,000.00 | $ 169,479.25 |
| Api Genesis LLC | Therapeutic Flavonoid Formulations | $ 244,479.25 | |
| Axon Nutritioinals Inc | Food and Therapeutic Supplement Development and Contaminant | $ 7,500.00 | $ 1,000.00 |
| Bioproximity, LLC | Amyloidosis Diagnostic Development via Global Proteomic Characterization | $ 76,303.90 | $ 64,787.94 |
| BIOSPHEREX LLC | Human Microblome Blowmarkers and Molecular Diagnostic Discovery Project | $ 58,692.50 | $ 185,786.75 |
| Biovista Inc | Dimebon (BVA-101) Drug Candidate for Projressive Multipie Sclerosis | $ 151,577.50 | $ 92,901.74 |
| Biovista, Inc | Dimebon (BVA-601) Drug Candidate for Epilepsy | $ 143,491.50 | $ 100,987.74 |
| Biovista, Inc. | Pirlindol Mesylate (BVA-201), Drug Candidate for Progressive Multiple Sclerosis | $ 171,976.00 | $ 72,503.24 |
| Cary Pharmaceuticals Inc. | Quitpak Smoking Cessation Drug | $ 5,600.22 | $ 238,879.02 |
| CEL-SCI CORPORATION | MULTIKINE IMMUNOTHERAPY AGENT FOR HEAD AND NECK CANCER ("Multikine") | $ 244,479.25 | |
| CEL-SCI Corporation | CEL-2000 Therapeutic drug for rheumatoid arthritis (CEL-2000) | $ 83,182.50 | $ 161,296.75 |
| CEL-SCI Corporation | Leaps H1N1 Therapeutic Agent for H1N1 Pandemic Influenza (Leaps H1N1) | $ 244,479.25 | |
| Ceres Nanosciences | Ceres Nanotrap | $ 170,228.00 | $ 74,251.25 |
| Clavgen Therapeutics LLC | Development of Universal Multivariate Biomarkers for Predicting Chemotherapeutic Response in Bladder and Ovarian Cancers | $ 195,820.48 | |
| Dalos BiopHARMA LLC | Flavokine's effect in basal cell carcinomas | $ 24,000.00 | |
| Dalos BioPharma, LLC | Flavokine's effect in Staphylococcus bacterial infections, including MRSA | $ 24,000.00 | |
| Diffusion Pharmaceuticals, LLC | Trans Sodium Crocetinate (TSC) for the Treatment of Hypoxic Conditions | $ 244,479.24 | |
| Dilon Technologies, Inc | BREAST SPECIFIC GAMMA IMAGING FOR EARLY DETECTION OF BREAST CANCER AND MONITORING OF TUMOR RESPONSE IN NEOADJUVANT CHEMOTHERAPY PATIENTS | $ 100,361.00 | $ 144,118.24 |
| Euclid Systems Corporation | Decorin Ophthalmic Solution | $ 244,479.24 | |
| EYERX Research, Inc. | Lacritin, a novel therapeutic for dry eye | $ 13,819.50 | |
| Gencia Corp | Pre-Clinical Development for the treatment of Alzheimer's and Sarcopenia | $ 224,164.00 | $ 20,315.25 |
| Gene Solutions, LLC | Parkinson's Disease Diagnostic Development | $ 17,147.50 | $ 5,352.50 |
| GPB Scientific, LLC | Therapeutic Stem Cells from Umbilcal Cord Blood | $ 244,479.25 | |
| Health Diagnostic Laboratory Inc | High Density Lipoprotein Associated Apolipoprotein E Quantitation | $ 244,479.25 | |
| Health Diagnostic Laboratory, Inc. | Vitamin and Mineral Testing for Nutritional Status | $ 244,479.25 | |
| HemoShear LLC | Human Surrogate Model of the Liver | $ 79,221.00 | $ 165,258.24 |
| HemoShear, LLC | Human Surrogate Diabetes Vascular Model | $ 244,479.24 | |
| Hypogen Inc | Targeted Therapeutics for Hypertension and/or Salt Sensitivity | $ 5,000.00 | |
| Hypogen Inc | Salt Sensitivity Urine Test | $ 5,000.00 | |
| Innovative Technologies, LLC | Breast Cancer Diagnostic Drug(ITL-1636) | $ 244,479.25 | |
| Instantlabs Medical Diagnostic Corporation | Enabling Accel. Real-Time Polymerase Chain Reaction (ART-PCR) at point -of-need | $ 244,479.25 | |
| Jericho Sciences, LLC | Novel Long-term Antiviral Therapeutic | $ 2,365.00 | $ 242,114.24 |
| John F. Hunt | Alkalinization of Inhaled Therapeutics. | $ 5,760.00 | $ 3,667.00 |
| Lestoni Corp | Targeting Tumor Hypoxia as New Cancer Therapy | $ 99,303.00 | $ 145,176.24 |
| Medgenics, Inc. | The Biopump Protein Factory | $ 244,479.25 | |
| Medical Predictive Science Corporation | Impact of HeRO Monitoring in Neonates | $ 244,479.24 | |
| Molecules for Health, Inc | Accelerating Development of Didox, a Unique Multifaceted Drug, Towards Clinical Usage | $ 32,518.00 | $ 119,588.50 |
| OCUCURE THERAPEUTICS, INC. | OC-10X: Topical treatment of Macular Degeneration and Diabetic Retinopathy | $ 244,479.24 | |
| OCULAR OPTICS, INC. | Sapphire TM Auto Focal IOL | $ 244,479.25 | |
| Osteologix Inc | NB S101 | $ 244,479.24 | |
| Parabon NanoLabs Inc | A novel Nano-Pharmaceutical for the treatment of Glioblastoma Multiforme | $ 38,352.47 | $ 92,028.90 |
| Phthisis Diagnostics, LLC | R-Sphere Cypto-Giardia Detect | $ 173,299.50 | $ 71,179.74 |
| Phtsisis Diagnostics, LLC | R-Sphere Microsporidia Detect | $ 35,916.50 | |
| PluroGen Therapeutics, Inc. | New Topical Antibiotic with Unique Antimicrobial, Physical, Bio-impace and Multi-function | $ 160,570.31 | $ 83,908.94 |
| Pocketsonics Inc | Pocket-Sized, Low-Cost, Ultrasound Imaging Device | $ 143,783.00 | $ 100,696.25 |
| Revivicor Inc | New therapies using human compatible cells and organs from genetically engineered pigs | $ 244,479.25 | |
| Skyentia Technologies LLC | Novel Therapeutic for Neuroprotection in Stroke and Traumatic Brain injury | $ 1,592.48 | $ 1,790.41 |
| SYNTHONICS INC | METALLO-ZANAMIVIR | $ 62,737.00 | $ 86,333.50 |
| Synthonics Inc | Metallo-SAHA | $ 64,834.50 | $ 76,873.00 |
| Synthonics Inc | Metallo - Topiramate | $ 61,746.50 | $ 66,791.50 |
| Synthonics, Inc | Metallo-Levodopa | $ 118,318.00 | $ 126,161.25 |
| Tau Therapeutics LLC | Interlaced Therapy with Mibefradil for the Treatment of Glioblastoma Multiforme | $ 169,518.52 | $ 74,960.73 |
| Techulon, Inc. | Glycofect Biodegradable Transfection Reagent | $ 48,619.50 | $ 84,000.00 |
| Toxem LLC | Botanical Drug for DIC in snakebite, sepsis and traumatic brain injury | $ 51,360.92 | $ 193,118.33 |
| WellAWARE Systems, Inc | WellAWARE | $ 244,479.25 | |
| Zansors LLC | Commercializing Micro/Nana sensors for obesity detection using bio-sensor technologies | $ 244,479.24 |
References/Related Topics
Page Last Reviewed or Updated: 2012-10-15
